Home » Stocks » ENTA

Enanta Pharmaceuticals, Inc. (ENTA)

Stock Price: $42.00 USD 0.98 (2.39%)
Updated Jul 23, 2021 4:00 PM EDT - Market closed
Market Cap 848.19M
Revenue (ttm) 94.16M
Net Income (ttm) -73.98M
Shares Out 20.17M
EPS (ttm) -3.68
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 23
Last Price $42.00
Previous Close $41.02
Change ($) 0.98
Change (%) 2.39%
Day's Open 41.09
Day's Range 40.90 - 42.13
Day's Volume 138,225
52-Week Range 40.32 - 56.97

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals Announces the Planned Retirement of Chief Medical Officer Nathalie Adda, M.D.

1 week ago - Business Wire

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals Presents New Data for EDP-721, an Oral HBV RNA Destabilizer, at the International Liver Congress (EASL)

1 month ago - Business Wire

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals Reports Positive Data from Phase 1b Study of EDP-514, a HBV Core Inhibitor, in Viremic Chronic HBV Patients

1 month ago - Business Wire

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals to Participate in Two Investor Conferences in June

1 month ago - Business Wire

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals to Present Preclinical Data for EDP-721, its Novel Oral HBV RNA Destabilizer, at the International Liver Congress™ 2021 - EASL

1 month ago - Business Wire

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals to Present at the RBC Capital Markets Global Healthcare Conference.

2 months ago - Business Wire

Enanta Pharmaceuticals Inc (NASDAQ: ENTA) has announced data from the first two dose cohorts of Part 2 of its Phase 1b study evaluating EDP-514 in chronic hepatitis B virus (HBV) patients already being ...

2 months ago - Benzinga

Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of -15.96% and -21.35%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2021 with Conference Call Today at 4:30 p.m. ET

2 months ago - Business Wire

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals Reports Positive Data from Part 2 of its Phase 1b Study of EDP-514 in Chronic HBV Patients on NUC Treatment

2 months ago - Business Wire

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta to Host Conference Call on May 6 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Second Quarter Ended March 31, 2021

2 months ago - Business Wire

Enanta Pharmaceuticals (ENTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals to Present at Upcoming Investor Conferences

4 months ago - Business Wire

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals to Present at SVB Leerink 10th Annual Global Healthcare Conference

5 months ago - Business Wire

Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of 50.00% and 19.26%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

5 months ago - Zacks Investment Research

Shares of Enanta Pharmaceuticals (NASDAQ:ENTA) were flat in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share decreased 163.08% year over year to ($0.41), ...

5 months ago - Benzinga

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2020 with Conference Call Today at 4:30 p.m. ET

5 months ago - Business Wire

Enanta Pharmaceuticals (NASDAQ:ENTA) unveils its next round of earnings this Monday, February 08. Get prepared with Benzinga's ultimate preview for Enanta Pharmaceuticals's Q1 earnings.

5 months ago - Benzinga

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals to Host Conference Call on February 8 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal First Quarter

5 months ago - Business Wire

Enanta Pharmaceuticals (ENTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

5 months ago - Zacks Investment Research

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals Announces the Appointment of Brendan Luu as Senior Vice President, Business Development

5 months ago - Business Wire

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals to Provide Updates on its R&D Programs and Outlook for 2021 at the 39th Annual J.P. Morgan Healthcare Conference

6 months ago - Business Wire

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals Announces the Appointment of John P. DeVincenzo, M.D. as Vice President of Translational Virology

6 months ago - Business Wire

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference

6 months ago - Business Wire

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals Announces the Appointment of Tara L. Kieffer, Ph.D. as Senior Vice President, New Product Strategy and Development

7 months ago - Business Wire

Enanta Pharmaceuticals, Inc. (ENTA) CEO Jay Luly on Q4 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of 40.22% and -7.80%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

8 months ago - Zacks Investment Research

Shares of Enanta Pharmaceuticals (NASDAQ:ENTA) were flat in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share decreased 431.82% over the past year to ($1.4...

8 months ago - Benzinga

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2020

8 months ago - Business Wire

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals to Present at Upcoming Conferences

8 months ago - Business Wire

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta to Host Conference Call on November 23 to Discuss Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2020

8 months ago - Business Wire

Enanta Pharmaceuticals (ENTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

8 months ago - Zacks Investment Research

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals to Present at the 4th Annual H.C. Wainwright Virtual NASH Investor Conference

9 months ago - Business Wire

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals Initiates Phase 1 Clinical Study of EDP-297, its Highly Potent and Targeted Follow-On Farnesoid X Receptor Agonist for NASH

10 months ago - Business Wire

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals to Participate in Upcoming September Conferences

10 months ago - Business Wire

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals Presents New Data from its Hepatitis B and Non-Alcoholic Steatohepatitis Programs at the Digital International Liver Congress

10 months ago - Business Wire

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals Announces Data Presentations at European Association for the Study of the Liver’s (EASL) Digital International Liver Congress

11 months ago - Business Wire

Enanta Pharmaceuticals, Inc. (ENTA) CEO Jay Luly on Q3 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of 2.74% and -37.56%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

11 months ago - Zacks Investment Research

Shares of Enanta Pharmaceuticals (NASDAQ:ENTA) were flat after the company reported Q3 results.

11 months ago - Benzinga

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2020 with Webcast and Conference Call Today at 4:30 p.m.

11 months ago - Business Wire

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals to Present at the BTIG Virtual Biotechnology Conference 2020

11 months ago - Business Wire

Enanta Pharmaceuticals (ENTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

11 months ago - Zacks Investment Research

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals to Host Conference Call on August 4 at 4:30 p.m.

11 months ago - Business Wire

Enanta Pharmaceuticals (ENTA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

1 year ago - Zacks Investment Research

Enanta Pharmaceuticals, Inc. (ENTA) CEO Jay Luly on Q2 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of 58.90% and -9.92%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

Given the urgent need for curing infected COVID-19 patients, we take a look at companies developing drugs/treatments for the same.

Other stocks mentioned: GILD, LLY, MRNA, REGN, RHHBY, SNY
1 year ago - Zacks Investment Research

The following are the latest biotech announcements from late Thursday and Friday morning on the development of products targeting the coronavirus.

Other stocks mentioned: AYTU, CANF, LJPC, LLY, OPK, RHHBY
1 year ago - Benzinga

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q1 2020 Results Conference Call February 6, 2020 4:30 PM ET

1 year ago - Seeking Alpha

About ENTA

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company offers glecaprevir for the treatment of chronic hepatitis C virus, or HCV under the MAVYRET and MAVIRET names. Enanta Pharmaceuticals, Inc. has a collaborative development and license agreement with Abbott Labo... [Read more...]

Industry
Biotechnology
IPO Date
Mar 21, 2013
CEO
Jay Luly
Employees
141
Stock Exchange
NASDAQ
Ticker Symbol
ENTA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 8 analysts, the average rating for ENTA stock is "Hold." The 12-month stock price forecast is 68.14, which is an increase of 62.24% from the latest price.

Price Target
$68.14
(62.24% upside)
Analyst Consensus: Hold